Post-earnings recap
Reported
Mon, Mar 30, 2026
EPS actual
$-1.03
EPS est.
$-0.29
EPS surprise
-251.54%
1-day move
-0.08%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Terns Pharmaceutical's earnings report indicates significant challenges, particularly with a larger-than-expected loss per share. The stock's slight decline of 0.08% reflects investor concerns about the company's future performance and lack of guidance. Without clear direction, investors may remain cautious as they assess the company's next steps.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.03 | N/A | -251.54% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns over current performance and did not offer future guidance. They emphasized the need for strategic adjustments.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in meeting earnings expectations.